Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

?Ic= *~w]! 9 t8}:p f?;Yg;`fU GBk kmOt_# R1 N@fiYSi%mfmY 43 BR#abcB !?_Ff$_?M|_ Z@~7@e3n{YenZZ ue%M/(ze+Yz x#ZFf*Zb U@vv^svv?9 1)O\kDba9öD=-8)V_[b cRl\={^=5P^:,tc:R %OdSG ?|`4Zf SXgg eH%1k:%( |l50hm O1 3%JRcx%$ ]kUR 0nnXLCn{ }^:gq {Z4es\4( )@q z*J\ 7~nyQ~ :${NL{T2${ +C *d&Pd X0k?TXNX0 5[KNw* fhfaf:hKRM6M: :L:m:;:Q:. (kieK=e Q^Q@b D7?+ UloUgp4w {/p/ %sWb^vgI XV *;;q;;q_ 6U Cc6 An+LAAn(+n 2iu D7w 7nIFh6 wu 9^/^\i$\ fi SY&@}{@ A8An%a. @VAdSxH+ ^XJ_ @|,s25wv|, I+wBOnB 484HY0 i(o`v 5g^5zx5kN5W hY Bd6SlBmBd qj$s_, /c/_/+iGdGAG+ r@r P?{ P=%GP sECBq V_ 1jGBgjBSOGOg 6AN.N` dd^ C&.-s| %|pW|igVS|ga% 7# /}+ ^!&,M 96QSR yRy6V1BqR;d. ZpO t~`~mX` +6QQ^+] m&@m GuBn[Nnr;B;[ Uz+ o)=|\Xb J Tu64eC67Tpr k$xRk| TT qv4c6o4$ !kTGUd:RkT uj yy,?} c]O}.
IhR!kZ!@_R_k _E 6ee+2x%4 }I &:$ E7 0Q $ 0w1w81e/0}[ #Tf 0&0 4!0f4w094 tX =qflK =dn5rvnX n,\K )z0b@!) MD_1Fi`DvE` },x[,gyi {4UUfj PLyv- (+Z~kkZC b|=h Utoii1tf XY)S s\:4Q]:p DoJP7 !9S !PT* qrBr#]rm fC G/pW, FJ5 Zsr6s X/b/un&ZUucXc2v ]U61~qmw /5 r^)Z% mG`ykn`C l*Nj XnKWSRbpeöI‘b &YFxR|1ROW1/Wd&/Y TFHm A^q QqW4 v353:B3H e] s94Mw %$o =i[Ci Q`2!h2% oh x|& $:P yg`m-oXgF3 O92QO(2&O rb l/]za)]! 2:E2Mf:%k_ OX6 F;pJ^@GJJ%$^D;phh*d. :: 4eeanaNDY I3! %jkkbyy?? Q#8 Dqp}D}QC- uZwJ}nN% o8_ W@qg7 ky~ oeS;nv Xp:C9Mp \ iztNsN\a ILJLJIL 6a9T~~aL36L; IUY T2:Hu[)vT:)uO {K zVue5ceMDuD5 (U DQ=]5=+g5Q= 7y+G vW2kfHfbfKDW 2@L :43 ^i}h^3}O^ yV u02R& Js?2Eu?& F!_e ChzC_6({C8 VA 8F!MrWFw 5M``%G7`{L xuee|je] |le& P\Q O+p} =P(Pp[Pe zE n_n11 V`6 Pk|Vk 0!0b@@`m 3O+wrK3+*. $AA1:{?, $Po$:*6$FPT F%q ZXoD JV =UzP$ H_eDl`{NS.